IXHL Stock Analysis: Buy, Sell, or Hold?
IXHL - Incannex Healthcare Limited American Depositary Shares
$3.71
0.01 (0.27%)
▲
5d:
-3.64%
30d:
-1.59%
90d:
+1217.94%
BUY
HIGH Confidence
Analysis Updated: May 20, 2026 12:00 AM ET
Earnings: May 21, 2026
0d
Get Alerted When IXHL Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: IXHL trading at deep discount. Market pricing in -8.5% annual earnings decline, creating value opportunity for patient investors.
✅ BUY SIGNAL: IXHL trading at deep discount. Market pricing in -8.5% annual earnings decline, creating value opportunity for patient investors.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$6.71
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$4.17
10.9% Margin of Safety
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 3.8x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IXHL is currently trading at $3.71, which is considered slightly low relative to its 30-day fair value range of $3.65 to $4.46. From a valuation perspective, the stock is trading at a discount (Forward PE: 2.9) compared to its historical average (3.8). Remarkably, the market is currently pricing in an annual earnings decline of 8.5% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, IXHL is in a strong uptrend. Immediate support is located at $3.52, while resistance sits at $5.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IXHL is in a strong uptrend. Immediate support is located at $3.52, while resistance sits at $5.00.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$3.65 -
$4.46
Company Quality Score
51/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
Trading Range Analysis
30-Day Trading Range
$3.65 -
$4.46
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$3.52
Resistance Level
$5.00
Current Trend
Strong Uptrend
Technical data as of
May 20, 2026
Fundamental Context
Forward P/E (Next Year Est.)
2.94
Revenue Growth (YoY)
-100.0%
Valuation Discount vs History
-8.5% cheaper
PE vs Historical
2.9 vs 3.8
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-8.5%
(market-implied from PE analysis)
1-Year Target
$3.39
(-9%)
2-Year Target
$3.11
(-16%)
3-Year Target
$2.84
(-23%)
3-Yr Target (if PE normalizes)
(PE: 3→4)
$3.67
(-1%)
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 2.9 to 3.8
Stabilization Target:
$4.79
(+29.1%)
PE Expansion Potential:
+29.1%
Share & Embed Analysis
Last updated: May 20, 2026 8:52 PM ET
Data refreshes hourly during market hours. Next update: 9:52 PM
Data refreshes hourly during market hours. Next update: 9:52 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IXHL showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 60 HOLD |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$131 | 56 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$104 | 63 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 54 HOLD |
|
AVDL
Avadel Pharmaceuticals P… |
STRONG BUY
8 analysts |
$21 | 62 BUY |
